Compare IDEXX Laboratories, Inc. (IDXX) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Vistra Corp — how do they compare? IDEXX Laboratories, Inc. trades at $516.57 (market cap $40.43B), while Vistra Corp trades at $161.23 (market cap $52.41B). The key difference: Vistra Corp is the larger of the two by market cap, and Vistra Corp pays a 0.59% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Vistra Corp for 32 Days on average.
| IDXX | VST | |
|---|---|---|
Market Cap | $40.43B | $52.41B |
Volume | 692,164 | 11,278,074 |
Sector | Health | Utilities |
52-Week High | $766.68 | $210.85 |
52-Week Low | $504.70 | $134.71 |
Typical Hold Time | 46 Days | 32 Days |
Enterprise Value | $41.32B | $74.34B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Vistra Corp. (VST) trades at $160.84, down 3.53% over the past day, amid mixed quarterly earnings but strong analyst support. The stock shows a bullish technical trend with support at $152 and resistance at $164, while fundamentals reflect robust profitability with an 11.55% net income margin and 75.73% ROE. Recent developments include a $4.2 billion US loan to expand nuclear power output and a 20-year power supply agreement with New Era Energy, positioning Vistra to capitalize on AI-driven electricity demand.
Outlook remains positive given Wall Street's consensus price target of $215.23, implying 34% upside, though risks include earnings volatility and high valuation multiples. Investment appeal hinges on execution of growth initiatives in nuclear and data center power markets, with institutional confidence underscored by Peter Thiel's significant stake.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
